Abstract: A method for improving the oxygen-releasing ability of hemoglobin, hemoglobin variants, recombinant hemoglobin or hemoglobin-based blood substitutes to organs or peripheral tissues in human bodies is disclosed by administering a compound of phthalides to a subject in need thereof. The compound of phthalides is characterized by a phthalide functional group which is represented as Formula I, and forms at least one hydrogen bond with ?Arg141 of hemoglobin, hemoglobin variants, recombinant hemoglobin or hemoglobin-based blood substitutes, stabilizing the ?1/?2 interface of hemoglobin, further stabilizing the oxygenated hemoglobin, hemoglobin variants, recombinant hemoglobin or hemoglobin-based blood substitutes in the low oxygen affinity “T” state and facilitating the oxygen release to the organs or the peripheral tissues.

Abstract: A method for improving the oxygen-releasing ability of hemoglobin, hemoglobin variants, recombinant hemoglobin or hemoglobin-based blood substitutes to organs or peripheral tissues in human bodies is disclosed by administering a compound of phthalides to a subject in need thereof. The compound of phthalides is characterized by a phthalide functional group which is represented as Formula I, and forms at least one hydrogen bond with ?Arg141 of hemoglobin, hemoglobin variants, recombinant hemoglobin or hemoglobin-based blood substitutes, stabilizing the ?1/?2 interface of hemoglobin, further stabilizing the oxygenated hemoglobin, hemoglobin variants, recombinant hemoglobin or hemoglobin-based blood substitutes in the low oxygen affinity “T” state and facilitating the oxygen release to the organs or the peripheral tissues.

Abstract: A method for improving the oxygen-releasing ability of hemoglobin, hemoglobin variants, recombinant hemoglobin and hemoglobin-based blood substitutes to organs and peripheral tissues in human bodies is disclosed by administering a compound of phthalides to a subject in need thereof to improve the oxygen-releasing ability of hemoglobin, hemoglobin variants, recombinant hemoglobin and hemoglobin-based blood substitutes to the organs and the peripheral tissues in human bodies. The compound of phthalides is characterized by a phthalide functional group, and forms at least one hydrogen bond with ?Arg141 of hemoglobin, hemoglobin variants, recombinant hemoglobin and hemoglobin-based blood substitutes, stabilizing the ?1/?2 interface of hemoglobin, further stabilizing the oxygenated hemoglobin, hemoglobin variants, recombinant hemoglobin and hemoglobin-based blood substitutes in the low oxygen affinity “T” state and facilitating the oxygen release to the organs and the peripheral tissues.

Abstract: A method for improving the oxygen-releasing ability of hemoglobin to organs and peripheral tissues in human bodies is disclosed by administering ferulic acid to a subject in need thereof to improve the oxygen-releasing ability of hemoglobin to the organs and the peripheral tissues in human bodies. Ferulic acid forms a hydrogen bond with ?Val1 of hemoglobin, stabilizing the ?1/?2 interface of hemoglobin, further stabilizing the oxygenated hemoglobin, hemoglobin variants, recombinant hemoglobin and hemoglobin-based blood substitutes in the low oxygen affinity “T” state and facilitating the oxygen release to the organs and the peripheral tissues.